Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
Citations Over TimeTop 1% of 2014 papers
Abstract
To improve both the homogeneity and the stability of ADCs, we have developed site-specific drug-conjugating reagents that covalently rebridge reduced disulfide bonds. The new reagents comprise a drug, a linker, and a bis-reactive conjugating moiety that is capable of undergoing reaction with both sulfur atoms derived from a reduced disulfide bond in antibodies and antibody fragments. A disulfide rebridging reagent comprising monomethyl auristatin E (MMAE) was prepared and conjugated to trastuzumab (TRA). A 78% conversion of antibody to ADC with a drug to antibody ratio (DAR) of 4 was achieved with no unconjugated antibody remaining. The MMAE rebridging reagent was also conjugated to the interchain disulfide of a Fab derived from proteolytic digestion of TRA, to give a homogeneous single drug conjugated product. The resulting conjugates retained antigen-binding, were stable in serum, and demonstrated potent and antigen-selective cell killing in in vitro and in vivo cancer models. Disulfide rebridging conjugation is a general approach to prepare stable ADCs, which does not require the antibody to be recombinantly re-engineered for site-specific conjugation.
Related Papers
- → On methylene‐bridged cysteine and lysine residues in proteins(2016)22 cited
- → Conversion of Bacillus subtilis OhrR from a 1-Cys to a 2-Cys Peroxide Sensor(2008)30 cited
- → Methodology for Determining Disulfide Linkage Patterns of Closely Spaced Cysteine Residues(2009)16 cited
- → The activation reaction of papain(1967)74 cited
- The 60Co gamma-radiolysis of aqueous papain solutions: repair and protection by cysteine.(1971)